USA Change Macroaxis User Registration

Home Portfolios Solutions About Us

More ROI Blog

Marketplace Community ScreenersEfficient FrontierCorrelationsRisk/Return

US Market Open: Feb 9, 15:31 PM 2012

NYSE 8088.04 5.06 Index Moved Up

NASDAQ 2928.69 12.83 Index Moved Up

and more..

sponsered by

Processing
Collecting necessary data for NKTR...

Nektar financials and fundamentals

Companies

Sectors

Advisers

More Actions
- Equity Search
- Advanced Search
- Filter Tops
- Adviser Directory
- Suggest Portfolio
- Backtest Watchlist
- Analyze Correlations
- View Transactions
- Check Volatility
- Import Equities

7.05

Intraday

One Month

^(0.16)

2.22%

4.07

Year To Date

11.25

6.97

Trading Day

7.35

Embed Now

Diversification Suggestion

Use Nektar to protect against small markets fluctuations. The stock experiences unexpected downward movement. The market is reacting to new fundamentals

1 Month Beta vs NYSE ......... 0.02

As returns on NYSE increase, Nektar returns are expected to increase less then the market. However, during bear market, the loss on holding Nektar will be expected to be smaller as well

NKTR

NASDAQ

Nektar Therapeutics

http://www.nektar.com

415-482-5300

Trade Nektar

Run Report

Correlation

Biotechnology

Market Capitalization 806.7M

Earnings Per Share -1.103

Today Lowest 6.97

Book Value Per Share 2.017

Howard W. Robin

Chief Officer, Pres and Director

John Nicholson

Chief Financial Officer and Sr. VP

Gil M. Labrucherie J.D.

Sr. VP, Gen. Counsel and Sec.

Stephen K. Doberstein Ph.D.

Chief Scientific Officer and Sr. VP

Rinko Ghosh

Chief Bus. Officer and Sr. VP

Nektar fundamentals

Open	7.19	P/B Ratio	3.57
Volume	604171	Sector	Healthcare
Last Close	7.21	Founded	Yes
Short Ratio	14.90	Last Traded	2/9/2012
Year High	11.25	Percent Change	2.22%
Year Low	4.07	Absolute Change	0.16
EPS	-1.103	Index Membership	Not Applicable
Employees	408	Day High	7.35
Day Low	6.97	Target Price	10.67
Current EPS	-1.103	This Year EPS	-1.33
Next Year EPS	-1.38	Current PE	Not Applicable

Nektar Performance

Embed Financials for Nektar Therapeutics

Nektar Profile

Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms.

IXIC		0.44 %
GSPC		0.21 %
NYA		0.06 %
NKTR		2.22 %

Live Sentiment

MWHYX

NASDAQ

Bought over 100 shares of

Metropolitan West High Yield B

12 minutes ago

for 10.1

CYS

NYSE

Bought over 300 shares of

Cypress Sharpridge Investments

12 minutes ago

for 13.37

SDY

N/A

Bought over 200 shares of

SPDR S&P Dividend

13 minutes ago

for 56.02

KGSCX

NASDAQ

Bought over 500 shares of

Kalmar Growth With Value Small

13 minutes ago

for 17.2

MACSX

NASDAQ

Bought over 500 shares of

Matthews Asian Growth And Inco

13 minutes ago

for 16.25

Nektar 30-Days Moving Rating

Macroaxis Total Score

Current 30 Days Moving Rating

Estimated Market Risk

3.02

actual daily

49 %

of total potential

Expected Return

0.67

actual daily

53 %

of total potential

Risk-Adjusted Return

0.22

actual daily

14 %

of total potential

Based on monthly moving average [ change ]

Increase Risk-Adjusted return of NKTR by adding it to a well-diversified portfolio

Diversify

Nektar Last Intraday

(0.16) Macroaxis: -0.16 Up

2.22%

7.21,7.21,7.05,7.05,7.35,6.97,7.05

7.21

7.05

Latest headlines for Nektar

Few days ago at jutiagroup.com

The Best Way to Invest in Biotech Stocks

Jutia Group - Jan 26, 2012 By Street Authority, on January 26th, 2012 in Street Authority The appeal of finding the right biotech stock is self-evident. If you get it right, and a cutting-edge biotech scores a major win with a breakthrough drug treatment, then you can score huge ...

Few days ago at jutiagroup.com

The Best Way to Invest in Biotech Stocks

Few days ago at www.fnno.com

Novartis had the Lowest Relative Performance in the Pharmaceuticals Industry ...

Novartis had the Lowest Relative Performance in the Pharmaceuticals Industry ... Financial News Network Online - Jan 23, 2012 Here are 5 stocks in the Pharmaceuticals industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were underperforming.

Few days ago at www.fnno.com

Novartis had the Lowest Relative Performance in the Pharmaceuticals Industry ...

Few days ago at seekingalpha.com

Nektar Therapeutics: Often Forgotten, But Worth A Look

Seeking Alpha - Jan 23, 2012 A few weeks into 2012, it looks like investors are much more eager to take on some risk in their portfolios and biotechs are coming back into favor.